
80 Actual / FMB



National Cancer Institute

1980 NCI FACT BOOK

U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Institutes

of Health

NATIONAL CANCER PROGRAM

National Cancer Institute

1980 NCI FACT BOOK



Revised December 1980 NIH Publication No. 81-512 April 1981

PREFACE

The information set forth in this publication is compiled and amended annually by the Financial Management Staff of the National Cancer Institute and is intended primarily for use by members of the Institute staff, the principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Manager, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland 20205.

TABLE OF CONTENTS

Preface	PAGE
	•
GENERAL INFORMATION	
Directory of Personnel	
Director, NCP/NCI – President's Cancer Panel	3
Organizational Tables: National Cancer Institute	7
Division of Cancer Biology and Diagnosis	10
Division of Extramural Activities	11
Actual vs. Constant Dollar Funding	14
Estimated Cancer Deaths and New Cases by Sex and Site	17
BUDGET DATA	
NCI Budget Administration Process NCI Extramural Funds—FY 1980 National Cancer Institute Budget History by Mechanisms NCI Research Programs—Fiscal Year 1980 Total NCI Dollars by Mechanisms—Fiscal Year 1980 NCI Program Structure—Fiscal Year 1980 Cancer Control Obligations—Fiscal Years 1973-1980 Reimbursement to NIH Management Fund—Fiscal Year 1980	22 24 25 25 26
GRANTS AND CONTRACTS	
NCI Grants Administration Process—Under Cancer Act of 1971 NCI Contracts Administration Process—Under Cancer Act of 1971 State Distribution of NCI Grant and Contract Dollars—Fiscal Year 1980 State Distribution of Cancer Control Grant and Contract Dollars—Fiscal Year 1980 Institutions Receiving More Than \$1,000,000 from the NCI—Fiscal Year 1980 Distribution of NCI Contract Dollars—Fiscal Year 1980 By Program	30 31 32
By Frogram By Institution	J.
HISTORY TABLES	
Appropriations of NCI – 1938-1981	40 41 42

DIRECTORY OF PERSONNEL

NATIONAL CANCER INSTITUTE NATIONAL INSTITUTES OF HEALTH BETHESDA, MARYLAND 20014

NIH Operator 496-4000 Area Code 301

		DIRECT-IN
DIRECTOR	BUILDING 31	DIALING
Dr. Vincent T. DeVita, Jr.	11-A-52	496-5615
ASSISTANT DIRECTOR	BUILDING 31	
Dr. Bayard H. Morrison III	11-A-46	496-3308
ASSISTANT DIRECTOR	BUILDING 31	
Dr. Richard A. Tjalma	3-A-16	496-5854
ASSOCIATE DIRECTOR FOR PROGRAM PLANNING AND ANALYSIS	BUILDING 31	
Mr. Louis M. Carrese	10-A-52	496-6445
CHIEF, PROGRAM ANALYSIS AND FORMULATION BRANCH	BUILDING 31	
Dr. Michael Klein, Acting	10-A-49	496-6445
CHIEF, SYSTEMS PLANNING BRANCH	BUILDING 31	
Ms. Barbara Murray, Acting	10-A-49	496-5515
ASSOCIATE DIRECTOR FOR MEDICAL APPLICATIONS OF CANCER RESEARCH	BUILDING 31	100 101
Dr. Diane J. Fink, Acting	11-A-29	496-1316
ASSOCIATE DIRECTOR FOR CANCER COMMUNICATIONS	BUILDING 31	400.000
Mr. J. Paul Van Nevel	10-A-29	496-663.
CHIEF, INFORMATION RESOURCES BRANCH	BUILDING 31	400 000
Mr. J. Paul Van Nevel, Acting	10-A-18	496-6631
CHIEF, REPORTS AND INQUIRIES BRANCH Dr. Robert M. Hadsell	BUILDING 31	405 5541
Dr. Robert W. Hadsell	10-A-29	496-6641
CHIEF, INFORMATION PROJECTS BRANCH Mr. Robert Denniston	BUILDING 31	406 6703
Wir. Robert Denniston	4-D-39	490-0793
SSOCIATE DIRECTOR FOR INTERNATIONAL AFFAIRS	BUILDING 31	106 176
Dr. Gregory T. O'Conor	11-A-19	496-4/6]
SSOCIATE DIRECTOR FOR ADMINISTRATIVE MANAGEMENT Mr. Philip Amoruso, Executive Officer	BUILDING 31	406 5707
Mr. Philip Amoruso, Executive Officer	11-A-49	496-5/3/
M D I I M N	BUILDING 31	405 5707
Mr. Robert M. Namovicz, Deputy Executive Officer	11-A-46	496-5/3/
CHIEF, ADMINISTRATIVE SERVICES BRANCH Mr. James Prather	BUILDING 31	405 5001
Mr. James Pratner	11-A-29	496-5801
CHIEF, FINANCIAL MANAGEMENT BRANCH	BUILDING 31	1000000
Mr. John P. Hartinger	11-A-18	496-5803
CHIEF, PERSONNEL MANAGEMENT BRANCH Ms. Marianne Wagner	BUILDING 31	0.000.000.000
Ms. Marianne Wagner	3-A-19	496-3337
CHIEF, RESEARCH CONTRACTS BRANCH	BLAIR BUILDING	\$244Aco (control o
Mr. James E. Graalman	B-16	496-3573
CHIEF, MANAGEMENT POLICY BRANCH	BUILDING 31	
Mr. Thomas L. Kearns	4-A-51	496-6985

		DIRECT-I DIALIN
FREDERICK CANCER RESEARCH CENTER	FREDERICK, MARYLAND BUILDING	3000
Dr. William W. Payne		FTS-8-935-730
ADMINISTRATIVE OFFICER	BUILDING	
Mr. Richard Carter		FTS-8-935-202
DIRECTOR, DIVISION OF CANCER CAUSE AND PREVENTION	BUILDING 31	
Dr. Richard Adamson, Acting	11-A-03	496-661
ADMINISTRATIVE OFFICER Mr. Stephen Ficca	BUILDING 31 11-A-11	496-655
DIRECTOR, DIVISION OF CANCER BIOLOGY AND DIAGNOSIS Dr. Alan S. Rabson ADMINISTRATIVE OFFICER Mr. Larry D. Willhite	BUILDING 31	
DIRECTOR, DIVISION OF CANCER TREATMENT Dr. Saul A. Schepartz, Acting	BUILDING 31	
DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES	BUILDING 31	
Dr. William A. Walter, Jr., Acting	10-A-03	496-514
ADMINISTRATIVE OFFICER Ms. Jean Stein	BUILDING 31 10-A-10	496-591
CHIEF, GRANTS ADMINISTRATION BRANCH Mr. Leo F. Buscher, Jr	WESTWOOD BUILDING 8-A-18	496-775
DIRECTOR DIVISION OF RESOURCES, CENTERS, AND COMMUNITY ACTIVITIES	BUILDING 31 4A-32	496-661
	4A-32	

or 10

NATIONAL CANCER INSTITUTE HISTORICAL DATA

LEGISLATIVE HIGHLIGHTS

- March 7, 1928—Senator M. M. Neely introduced S. 3554, "To authorize the National Academy of Sciences to investigate the means and methods for affording Federal aid in discovering a cure for cancer and for other purposes."
- July 23, 1937—The National Cancer Institute Act, introduced by Congressman Warren G. Magnuson, was passed by Congress. An appropriation of \$700,000 for each fiscal year was authorized.
- July 1, 1944 The Public Health Service Act, Public Law 410, 78th Congress provided that "The National Cancer Institute shall be a division in the National Institutes of Health." The act also revised and consolidated many revisions into a single law. The limit of \$700,000 annual appropriation was removed.
- December 4, 1970—Senator Ralph Yarborough, Texas, introduced S. 4564, "A bill which would establish a National Cancer Authority for the purpose of devising and implementing a national program for the conquest of the world's most dreaded disease—cancer."
- January 22, 1971 In his State of the Union Message, President Nixon announced that he would ask for the appropriation of an additional \$100 million to launch an intensive effort to control cancer, and that he would ask later for whatever additional funds could be effectively used.
- October 18, 1971 The President announced that the Army's Biological Defense Research Center at Fort Detrick, Maryland would be converted into a leading center for cancer research as part of the major campaign to conquer cancer.
- **December 7, 1971**—After three conference sessions that began on November 30, the Senate-House Conference Committee agreed on an expanded cancer program.
- December 23, 1971—The President signed P. L. 92-218, The National Cancer Act of 1971, providing increased authorities and responsibilities for the NCI Director; initiating a National Cancer Program; establishing a three-member

- President's Cancer Panel and a 23-member National Cancer Advisory Board; establishing cancer control programs as necessary for cooperation with State and other health agencies, and providing for the collection, analysis, and dissemination of all data useful in the diagnosis, prevention, and treatment of cancer, including the establishment of an international cancer research data bank.
- January-February 1974 Hearings were held on the proposed legislation to improve on the National Cancer Plan and to authorize appropriations for the next three years.
- July 23, 1974—The National Cancer Act Amendments of 1974, P.L. 93-352, was signed. The Amendments: encourage the NCP to explore the role of nutrition in the treatment, rehabilitation, and causation of cancer; authorize the Director to include personnel needs in the budget estimate to OMB; remove the limit on the number of comprehensive cancer centers; increase the number of expert appointments to 100; and direct the NCI to provide and contract for a program to disseminate and interpret information respecting the cause, prevention, diagnosis and treatment of cancer.
- August 1, 1977—The Biomedical Research Extension Act of 1977, P.L. 95-83, increased the number of expert appointments from 100 to 151.
- November 9, 1978—The Biomedical Research and Training Amendments of 1978, P.L. 95-622, was signed into law. The amendments redefined the National Cancer Program to highlight prevention activities; expanded the membership of the National Cancer Advisory Board to 29 members, identifying a minimum of 5 to be knowledgeable in environmental and occupational carcinogenesis and 2 to be physicians primarily involved in treating cancer patients; added basic research to the cancer centers authority; authorized travel and moving expenses to and from duty station for experts; and emphasized education and information in all aspects of the National Cancer Program.

- August 5, 1937—President Franklin D. Roosevelt signed the National Cancer Act.
- November 9, 1937 The National Advisory Cancer Council held its first meeting
- January 13, 1938—Dr. Carl Voegtlin was appointed the first Director of the Institute.
- October 31, 1940 President Franklin D. Roosevelt dedicated Building 6.
- July 1, 1947—NCI reorganized to provide for expanded program; intramural cancer research, cancer research grants, and cancer control activities.
- July 2, 1953—NCI inaugurated a full-scale clinical research program in the new Clinical Center.
- April 1955—The Cancer Chemotherapy National Service Center was established in the Institute to coordinate the first national, voluntary, cooperative cancer chemotherapy program.
- January 11, 1966—NCI reorganized to coordinate related activities. The areas of three Scientific Directors were established: Etiology; Chemotherapy; and a group of discipline-oriented laboratories and branches referred to as General Laboratories and Clinics.
- February 13, 1967—A Cancer Research Center was established in Baltimore USPHS Hospital to conduct an integrated program of laboratory and clinical research on the therapy and management of cancer patients.
- April 27, 1970 At the request of Senator Ralph W. Yarborough, Chairman of the Committee on Labor and Public Welfare, the Senate approved the establishment of the National Panel of Consultants on the Conquest of Cancer.
- October 18, 1971 President Nixon converted the Army's former biological warfare facilities at Fort Detrick, Md., to research on the causes, treatment and prevention of cancer.
- **December 23, 1971**—President Nixon signed P.L. 92-218, The National Cancer Act of 1971.
- June 22, 1972—The Institute awarded a contract for the operation and maintenance of the Frederick Cancer Research Center at Fort Detrick, Maryland. This constituted the largest research contract ever awarded by a research component of the National Institutes of Health.

- June 30, 1972 A team of five U.S. cancer scientists met with Russian scientists in Moscow to exchange information on cancer drugs. Dr. C. Gordon Zubrod, Scientific Director for Chemotherapy, NCI, on behalf of the United States, signed a U.S.-U.S.S.R. agreement on the exchange of drugs, visiting scientists, and information.
- July 27, 1972—A Bureau-level organization was established for the National Cancer Institute, giving the Institute and its components organizational status commensurate with the responsibilities bestowed on it by The National Cancer Act of 1971. Under the reorganization, the Institute was composed of the Office of the Director and four Divisions; the Division of Cancer Biology and Diagnosis; Division of Cancer Cause and Prevention; Division of Cancer Treatment; and Division of Cancer Grants.
- September 10, 1974—NCI established the Division of Cancer Control and Rehabilitation, which will plan, direct and coordinate an integrated program of activities regarding the widespread application of available and new methods for reducing the incidence, morbidity and mortality from cancer.
- July 1975—The Division of Cancer Treatment was expanded to include the NCI Surgery and Radiation Oncology Branches and the extramural program of Cancer Cooperative Clinical Trials. The reorganization strengthened the Division's capabilities for conducting a national program of research on cancer treatment by combined modalities.
- May 15, 1978—The first phase of an extensive NCI reorganization was announced. Day-by-day administrative and funding responsibility for extramural research programs was consolidated in each of the four research divisions. Responsibility for grant and contract review committees and for other committee management activities was transferred to the Division of Cancer Research Resources and Centers.
- July 18, 1979—NCI and the National Naval Medical Center entered into an agreement to cooperate in a research program in cancer treatment at the Naval Medical facility.

DIRECTOR NATIONAL CANCER PROGRAM NATIONAL CANCER INSTITUTE

Vincent T. DeVita, Jr., M.D.

January 1, 1980 TO PRESENT

Dr. Vincent T. DeVita, Jr., received his B.S. degree in 1957 from the College of William and Mary and in 1961 received his M.D. degree with distinction from the George Washington School of Medicine. He interned at the University of Michigan Medical Center and then completed a year of residency with the George Washington University medical service. Dr. DeVita joined NCI in 1963 as a clinical associate, and after completing a senior residency at the Yale-New Haven Medical Center in 1965-66, returned to NCI as a senior investigator in the Solid Tumor Service and, in 1971, became Chief of the Medicine Branch. He was

named Director of the Division of Cancer Treatment in 1974 and, in 1975, Clinical Director of the Institute. In January 1980 he was appointed Acting Director, National Cancer Institute, and in July 1980, Director. Dr. DeVita serves on the editorial boards of numerous medical journals, maintains memberships in many scientific societies, and was President of the American Society of Clinical Oncology (1977-78). For his outstanding research and medical leadership, he has received a number of honors and awards, including the 1972 Albert and Mary Lasker Medical Research Award.

PRESIDENT'S CANCER PANEL	EXPIRATION OF APPOINTMEN
Dr. Joshua Lederberg, <i>Chairman</i> Rockefeller University New York, New York	1981
Dr. Harold Amos Harvard Medical School Boston, Massachusetts	1983
Dr. Bernard Fisher University of Pittsburgh Pittsburgh, Pennsylvania	1982

NATIONAL CANCER ADVISORY BOARD

APPOINTEES	EXPIRATION OF APPOINTMENT		EXPIRATION OF APPOINTMENT
Dr. Henry C. Pitot, Chairman University of Wisconsin Madison, Wisconsin	1982	Mrs. Vincent Lombardi Manalapan, Florida Dr. William E. Powers	1982 1986
Dr. Bruce N. Ames University of California Berkeley, California	1982	Harper Grace Hospital Detroit, Michigan Dr. Janet D. Rowley	1984
Dr. Maureen M. Henderson University of Washington Seattle, Washington	1984	University of Chicago Chicago, Illinois Mr. Sheldon W. Samuels AFL-CIO	1984
Dr. Robert C. Hickey M.D. Anderson Hospital and Tumor Insti Houston, Texas	1986 tute	Washington, D. C. Mr. Morris M. Schrier MCA, Inc.	1984
Dr. Joseph Gale Katterhagen Tacoma General Hospital Tacoma, Washington	1986	New York, New York Dr. Frederick Seitz The Rockefeller University	1982
Mrs. Rose Kushner Writer/Consumer Interest Kensington, Maryland	1986	New York, New York Dr. Irving J. Selikoff Mount Sinai School of Medicine New York, New York	1984
Ann Landers Field Newspaper Syndicate Chicago, Illinois	1986	Dr. Philippe Shubik German Cancer Center Federal Republic of Germany	1982
Dr. LaSalle D. Leffall Howard University Washington, D. C.	1986	Dr. Gerald N. Wogan Massachusetts Institute of Technology Cambridge, Massachusetts	1984
EX OFFICIO MEMBERS			

EX OFFICIO MEMBERS

Dr. John H. Moxley, III Assistant Secretary of Defense (Health Affairs) Washington, D. C.

Dr. Frank Press Office of Science and Technology Policy Washington, D. C.

Mr. Douglas Costle Environmental Protection Agency Washington, D. C.

Ms. Susan B. King Consumer Product Safety Commission Washington, D. C.

Mr. Raymond J. Donovan Secretary of Labor Washington, D. C.

Dr. Donald L. Custis Veterans Administration Washington, D. C.

ALTERNATES TO EX OFFICIO MEMBERS

Dr. F. Kash Mostofi Armed Forces Institute of Pathology Washington, D. C.

Dr. Denis J. Prager Office of Science and Technology Policy Washington, D. C.

Dr. Richard E. Marland Environmental Protection Agency Washington, D. C.

Dr. Peter W. Preuss Consumer Product Safety Commission Washington, D. C.

Dr. Victor Alexander Department of Labor Washington, D. C. Dr. Jere Edwin Goyan Food and Drug Administration Rockville, Maryland

Dr. Anthony Robbins
National Institute for Occupational Safety and Health
Rockville, Maryland

Dr. David P. Rall
National Institute of Environmental Health Sciences
Research Triangle Park, North Carolina

Mr. Richard Schweiker Secretary for Health and Human Services Washington, D. C.

Dr. Donald S. Fredrickson
Director, National Institutes of Health
Bethesda, Maryland


Dr. Marguerite T. Hays Veterans Administration Washington, D. C.

Dr. Gary Flamm Food and Drug Administration Rockville, Maryland

EXECUTIVE SECRETARY

Dr. William A. Walter
Acting Director, Division of Extramural Activities
National Cancer Institute, NIH
Bethesda, Maryland

NATIONAL CANCER INSTITUTE



OFFICE OF THE DIRECTOR Dr. Vincent T. DeVita, Jr. Director

Plans, develops, directs, and coordinates the activities and programs of the Institute and of the National Cancer Program; and provides overall administrative guidance and services.

PLANNING AND ANALYSIS Mr. Louis M. Carrese

Manages development of the National Cancer Program Plan, the annual 5-year plan, individual program plans, and the evaluation plan; analyzes programs of the Institute; evaluates resource needs for the National Cancer Program; develops and provides support for management and scientific information systems.

OFFICE OF CANCER COMMUNICATIONS Mr. J. Paul Van Nevel

Develops and manages the program communications activities of the NCI/NCP; interprets program and organizes, prepares and disseminates reports on cancer research for research institutions and other organizations participating in the NCP; maintains liaison with NCI constituents on behalf of the Director; responds to public inquiries; prepares and coordinates internal reports for dissemination within the Institute, the Executive Branch, and the Congress.

OFFICE OF INTERNATIONAL AFFAIRS Dr. Gregory T. O'Conor

Plans, coordinates, and manages cooperative international cancer research activities and provides leadership within the National Cancer Institute for the development of international programs and activities.

OFFICE OF ADMINISTRATIVE MANAGEMENT

Mr. Philip Amoruso Executive Officer Mr. Robert M. Namovicz Deputy Executive Officer

Directs, coordinates, and conducts administrative management activities of the Institute including: personnel, budget, contracts, and administrative services; advises Director on administrative management aspects of the program.

PROGRAM ANALYSIS AND FORMULATION BRANCH Dr. Michael Klein

SYSTEMS PLANNING BRANCH Ms. Barbara Murray (acting) INFORMATION RESOURCES BRANCH

Mr. E. Joseph Bangiolo

REPORTS AND INQUIRIES BRANCH

Dr. Robert M. Hadsell

INFORMATION PROJECTS BRANCH

Mr. Robert Denniston

ADMINISTRATIVE SERVICES BRANCH

Mr. Harley Husted (acting)

FINANCIAL MANAGEMENT BRANCH

Mr. John P. Hartinger

PERSONNEL MANAGEMENT BRANCH Ms. Marianne Wagner

RESEARCH CONTRACTS BRANCH

Mr. James E. Graalman

MANAGEMENT POLICY BRANCH

Mr. Thomas L. Kearns

DIVISION OF CANCER CAUSE AND PREVENTION

Dr. Richard Adamson, Acting Director

ADMINISTRATIVE MANAGEMENT BRANCH Mr. Stephen Ficca Plans and directs a national program of laboratory, field, and demographic research on the cause and natural history of cancer and means for preventing cancer through direct intramural research, research grants, and contracts; evaluates mechanisms of cancer induction by viruses and by environmental carcinogenic hazards; tests for carcinogenic potential of environmental agents; serves as the focal point for the Federal Government on the synthesis of clinical, epidemiological, and experimental data relating to cancer; and participates in the evaluation of and advises the Institute Director on program-related aspects of the other grant and cancer control activities as they relate to cancer cause and prevention.

BOARD OF SCIENTIFIC COUNSELORS Dr. Peter N. Magee, Chairman

FIELD STUDIES AND STATISTICS PROGRAM Dr. Joseph F. Fraumeni, Jr. (acting)

Plans, directs, coordinates, and evaluates a program of epidemiologic, statistical, and mathematical research activities and statistical and automatic data-processing services for all NCI research programs.

BIOASSAY PROGRAM Dr. John Moore (acting)

Plans, directs, and conducts a collaborative program for the in vivo and in vitro testing of chemical and physical agents in the environment for carcinogenic and co-carcinogenic effects; administers research in the development and evaluation of standardized methods, designs, and models for in vivo and in vitro carcinogenesis testing, related toxicology, and tumor pathology.

CARCINOGENESIS INTRAMURAL PROGRAM Vacant

Plans, implements, and administers the Institute's program of general laboratory research on cancer causation by chemical, physical, and biological (viral) factors, and on the pathogenesis and prevention of various cancers.

CARCINOGENESIS EXTRAMURAL PROGRAM Dr. John A. Cooper (acting)

Develops, evaluates, and administers the Institute's program of research grant, contract, and similarly supported extramural activities in cancer causation and prevention; responsible for program management, including improved management methods and practices, as well as maintaining liaison for extramural activities with various organizations and scientists.

BIOMETRY BRANCH Dr. Earl S. Pollack

CLINICAL EPIDEMIOLOGY BRANCH Dr. Robert W. Miller

ENVIRONMENTAL EPIDEMIOLOGY BRANCH Dr. Joseph F. Fraumeni, Jr.

TECHNICAL INFORMATION RESOURCES BRANCH Mr. Dalton C. Tidwell (acting)

TUMOR PATHOLOGY BRANCH Vacant

TOXICOLOGY BRANCH Vacant

LABORATORY OF TUMOR VIRUS GENETICS

Dr. Edward Scolnik

LABORATORY OF CELLULAR AND MOLECULAR BIOLOGY Dr. Stuart Aaronson

Dr. Joseph DiPaolo

LABORATORY OF MOLECULAR CARCINOGENESIS Dr. Harry V. Gelboin LABORATORY OF VIRAL CARCINOGENESIS Dr. George Todaro

LABORATORY OF CARCINOGEN METABOLISM Dr. Elizabeth Weisburger

LABORATORY OF EXPERIMENTAL PATHOLOGY Dr. Umberto Saffiotti

LABORATORY OF MOLECULAR VIROLOGY Dr. George Khoury (acting)

LABORATORY OF CHEMOPREVENTION Dr. Michael B. Sporn SPECIAL PROGRAMS BRANCH Dr. Donald Luecke

BIOLOGICAL CARCINOGENESIS BRANCH

Dr. James T. Duff

CHEMICAL AND PHYSICAL CARCINOGENESIS BRANCH Dr. Thaddeus Domanski PLANNING AND ANALYSIS BRANCH Dr. Ihor Masnyk

DIVISION OF CANCER BIOLOGY AND DIAGNOSIS

Dr. Alan S. Rabson, Director

Plans and directs the research activities of the National Cancer Institute relating to cancer biology and diagnosis; maintains surveillance over developments in its program and assesses the national need for research in cancer biology and diagnosis; and maintains the necessary scientific management capability to foster and guide an effective research program.

BOARD OF SCIENTIFIC COUNSELORS Dr. David Korn, Chairman

IMMUNOLOGY INTRAMURAL RESEARCH PROGRAM

Dr. Alan S. Rabson (acting)

Plans, directs, coordinates, and evaluates a program of basic research on immunology and cell biology, and applied research on tumor immunology; through intramural laboratories, administers research in basic immunology and cell biology, as well as applications of immunology and cell biology to studies of the biology, diagnosis, and treatment of neoplastic diseases.

LABORATORY OF CELL BIOLOGY Dr. Lloyd W. Law

LABORATORY OF IMMUNODIAGNOSIS Dr. Ronald Herberman

LABORATORY OF IMMUNOBIOLOGY Dr. Herbert J. Rapp

IMMUNOLOGY BRANCH Dr. David Sachs

EXTRAMURAL RESEARCH PROGRAM

Dr. Ihor Masnyk

Plans, directs, coordinates, and evaluates a program of basic and applied research and cancer biology and diagnosis and also monitors the professional aspects of research contract and grant management; and, through grants and research contracts, administers studies in the cancer biology and diagnosis of cancer.

DIAGNOSIS BRANCH Dr. K. Robert McIntire

BREAST CANCER PROGRAM COORDINATING BRANCH Dr. D. Jane Taylor

> CANCER BIOLOGY BRANCH Dr. Brian Kimes

INTRAMURAL RESEARCH PROGRAM

Dr. Alan S. Rabson (acting)

Plans, directs, coordinates, and evaluates a program of basic research on cancer biology and diagnosis; and, through intramural laboratories, administers research in basic cancer biology and diagnosis, as well as applications of cancer biology and diagnosis to studies in metabolism, dermatology, and pathology.

LABORATORY OF BIOCHEMISTRY Dr. Maxine Singer

LABORATORY OF PATHOPHYSIOLOGY Dr. Pietro M. Gullino

LABORATORY OF THEORETICAL BIOLOGY Dr. Mones Berman (acting) LABORATORY OF PATHOLOGY

Dr. Alan S. Rabson (acting)

LABORATORY OF MOLECULAR BIOLOGY Dr. Ira H. Pastan

METABOLISM BRANCH Dr. Thomas W. Waldmann

DERMATOLOGY BRANCH Dr. Stephen Katz

BOARD OF SCIENTIFIC COUNSELORS

Dr. Samuel Hellman, Chairman

ADMINISTRATIVE MANAGEMENT AND PLANNING BRANCH

Mr. Michael Goldrich

DIVISION OF CANCER TREATMENT

Dr. Saul Schepartz, Acting Director

Plans, directs, and coordinates an integrated program of cancer treatment activities with the objective of curing or controlling cancer in man by utilizing combination modalities including chemical, surgical, radiological, nutrition, antiemetic research, and certain immunological techniques, through intramural laboratory and clinical studies, contract and grant research, and research conducted in cooperation with other Federal agencies; administers a total drug development program encompassing all phases from drug acquisition up to and including clinical trials; and serves as the national focal point for information and data on experimental and clinical studies related to cancer treatment and for the distribution of such information to appropriate scientists and physicians.

SCIENTIFIC INFORMATION BRANCH

Ms. Susan M. Hubbard

BIOLOGICAL DEVELOPMENT BRANCH

Dr. Robert Oldham

BIOLOGICAL RESOURCES BRANCH

Dr. Robert Oldham

CLINICAL ONCOLOGY PROGRAM

Dr. Bruce Chabner

Plans, directs, coordinates, and evaluates patient care activities of the NCI and a program of basic, applied, and clinical research in cancer treatment.

MEDICINE BRANCH Dr. Robert C. Young

PEDIATRIC ONCOLOGY BRANCH Dr. Arthur S. Levine

NCI-VA MEDICAL ONCOLOGY BRANCH Dr. John Minna

RADIATION ONCOLOGY BRANCH Dr. Eli Glatstein

SURGERY BRANCH Dr. Stephen Rosenberg

CLINICAL PHARMACOLOGY BRANCH Dr. Bruce Chabner

BIOMETRICS RESEARCH BRANCH Dr. Richard Simon

BALTIMORE CANCER RESEARCH PROGRAM

Dr. Peter H. Wiernik (acting)

Plans, directs, coordinates, and evaluates a program of laboratory and clinical research carried on by the NCI Baltimore Cancer Research Center.

> CLINICAL ONCOLOGY BRANCH Dr. Peter H. Wiernik

LABORATORY OF MOLECULAR BIOLOGY Dr. Carl C. Levy

LABORATORY OF CLINICAL BIOCHEMISTRY Dr. Nicholas R. Bachur

CANCER THERAPY EVALUATION PROGRAM

Dr. John S. MacDonald

Plans, evaluates, and coordinates extramural clinical research programs testing combined modality approaches and the testing of investigational new agents; and directs the evaluation of the effectiveness of specific types and methods of cancer therapy and analyzes and assesses the applicability of new methods and agents in the clinical treatment of cancer.

INVESTIGATIONAL DRUG BRANCH Dr. Vincent H. Bono

BIOLOGICAL EVALUATION BRANCH Dr. John S. MacDonald (acting)

> RADIOTHERAPY DEVELOPMENT BRANCH Dr. David A. Pistenma

CLINICAL INVESTIGATIONS BRANCH Dr. William DeWys

DEVELOPMENT THERAPEUTICS PROGRAM

Dr. John Driscoll (acting)

Plans, directs, and conducts a basic and applied research program in the preclinical development of therapeutic modalities, especially those related to chemotherapy; and, through intramural laboratories and contracts, administers research in programmed preclinical evaluation of potential cancer therapeutic agents, molecular pharmacology and toxicology of drugs, and molecular biological aspects of neoplastic transformation.

DRUG SYNTHESIS AND CHEMISTRY BRANCH Dr. Ven Narayanan

NATURAL PRODUCTS BRANCH Dr. John D. Douros

PHARMACEUTICAL RESOURCES BRANCH Mr. J. Paul Davignon

TOXICOLOGY BRANCH Mr. Michael Lowe (acting)

DRUG EVALUATION BRANCH Dr. John M. Venditti EXTRAMURAL RESEARCH & RESOURCES BRANCH Dr. Moreshwar Nadkarni

PHARMACOLOGY
Dr. Richard Adamson

LABORATORY OF TUMOR CELL BIOLOGY Dr. Robert C. Gallo

LABORATORY OF MEDICINAL CHEMISTRY AND BIOLOGY Dr. David G. Johns

LABORATORY OF MOLECULAR PHARMACOLOGY Dr. Kurt W. Kohn

ANIMAL GENETICS AND PRODUCTION BRANCH Dr. Joseph G. Mayo (acting)

DIVISION OF RESOURCES, CENTERS, AND COMMUNITY ACTIVITIES Dr. William Terry, Acting Director

Plans and conducts research, evaluation, demonstration, technology transfer, education, and information dissemination programs to expedite optimal use of new information relevant to the prevention, detection, and diagnosis of cancer, and the pretreatment evaluation, treatment, rehabilitation, and the continuing care of cancer patients in the community and in cancer centers; plans, directs, and coordinates the support of cancer research at cancer centers and through organ site programs; plans and conducts basic and applied research programs in pain and rehabilitation; supports professional and paraprofessional clinical education, research training, and continuing education; and administers project grant programs for the construction, alteration, renovation, and equipping of basic and clinical research facilities.

BOARD OF SCIENTIFIC COUNSELORS (Chairmanship Vacant)

PREVENTION, DETECTION, AND DIAGNOSIS PROGRAM Vacant

Identifies new research findings that are of importance for prevention, early detection, or diagnosis; plans and conducts research necessary to further develop and ensure validity of measures for the prevention, early detection, or diagnosis of cancer and to evaluate such programs when applied to the general population; plans and conducts research to analyze, evaluate, and refine cancer prevention, detection, and diagnosis strategies to assure maximum benefits to the largest possible population with the least risk and cost; and demonstrates prevention, detection, and diagnosis activities in cancer centers and communities and in selected populations.

TREATMENT, CONTINUING CARE, AND REHABILITATION PROGRAM Vacant

Plans and conducts basic research programs in pain and rehabilitation; identifies new research findings that are of importance for treatment, continuing care, or rehabilitation of cancer patients; plans and conducts research to determine best methods for limiting morbidity and mortality of cancer through participation of community physicians, community hospitals, and other community agencies in the treatment of cancer; plans and conducts research necessary to further develop and ensure validity of measures for the continuing care or rehabilitation of cancer patients: plans and conducts research to determine best methods for implementing new research findings of importance for cancer treatment, continuing care, and rehabilitation to assure maximum benefits to the largest possible population with the least risk and cost; and demonstrates treatment, continuing care, and rehabilitation activities in cancer centers and communities.

RESEARCH RESOURCES PROGRAM Vacant


IN SECTION SECTION

Plans, directs, and evaluates a program of exploratory grants and care support grants for cancer research centers; plans and conducts coordinated research programs on cancers of high incidence, e.g., urinary bladder, large bowel, pancreas, and prostate through the Organ Site Programs; plans and conducts research resource activities including construction, professional and paraprofessional clinical education, research training, and continuing education; and develops additional research resources as needed.


DIVISION OF EXTRAMURAL ACTIVITIES

Dr. William A. Walter, Acting Director

Administers and directs the Institute's grant and contract review and processing activities; provides initial technical and scientific merit review of grants and contracts for the Institute; provides grants management for the Institute; represents the Institute on over-all NIH extramural and collaborative program policy committees, coordinates such policy within NCI, and develops and recommends NCI policies and procedures as related to the review of grants and contracts, coordinates the Institute's review of research grant and training programs with the National Cancer Advisory Board and the President's Cancer Panel; coordinates the implementation of committee management policies within the Institute and provides the Institute's staff support for the National Cancer Advisory Board and the President's Cancer Panel; coordinates program planning and evaluation in the extramural area; provides scientific reports and analyses to the Institute's grant and contract programs; provides financial data and analyses on grants and contracts to the Institute; and recommends to the Director, NCI, funding levels of extramural programs.



TOTAL NATIONAL RESOURCES FOR CANCER RESEARCH AND CANCER CONTROL—FISCAL YEAR 1980



NATIONAL CANCER PROGRAM STRATEGY

The essential and continuing goal of the National Cancer Institute (NCI) is the same today as it was when the Institute was created by an Act of Congress 40 years ago: To develop the means for reducing the incidence, morbidity, and mortality of cancer. The NCI continues to be the lead federal agency in cancer, responsible and accountable for the investment of progress toward that goal. However, the National Cancer Act of 1971 (amended in 1974 and 1978) brought about some changes which have had significant impact on cancer research. The most obvious impact has been that the level of support for cancer research and control activities with public funds has increased four-fold since 1971. But the mandate from Congress to intensify and expand the cancer effort has had other implications beyond the increase of resources for the National Cancer Program.

The 1978 amendment to the 1971 Cancer Act redefined the National Cancer Program (NCP) and stated that "The National Cancer Program shall consist of (1) an expanded, intensified, and coordinated cancer research program encompassing the research programs conducted and supported by the Institute and the related research programs of the other research institutes and including an expanded and intensified research program for the prevention of cancer caused by occupational or environmental exposure to carcinogens, and (2) the other programs and activities of the Institute." Thus, the Act not only provided the public with both a symbolic and operational entity with which to identify at the national level, but also brought about a greater spirit and degree of awareness, cooperation, and coordination among federal programs.

The National Cancer Program has three major program components:


- Research
- Control
- Support.

The first two components encompass the scientific and technical activities, while the support component includes those activities needed to carry out the research and control efforts effectively (e.g., construction and manpower development activities).

The addition of cancer control responsibilities to NCI's research responsibilities and through the specific emphasis placed on the expansion of comprehensive cancer centers as focal points for research, teaching, and demonstration, served to further emphasize the axiom that the ultimate purpose of disease research is to produce results that can be translated into improved methods for the prevention and treatment of disease in people, and that the National Cancer Program would invest significant effort and resources in this area.

One important characteristic of the NCP since its inception has been the extensive and continuous participation of the biomedical community in the major planning efforts of the NCI. Beginning with the development of the first edition of the National Cancer Program Plan in 1972, periodic planning sessions have been held for the purpose of revising and updating the major recommendations for research and control activities.

The general character of the Program has become increasingly the product of a more extensive and frequent interaction among Congress, the public, the biomedical community, and federal agencies. In particular, the consistent and active roles of the President's Cancer Panel and the National Cancer Advisory Board have established a model for effective and productive relationships between national advisory committees and the federal agency.



NUMBER OF DEATHS FOR THE FIVE LEADING CANCER SITES BY AGE GROUP AND SEX — 1978

TOT	AL	UNDE	UNDER 15		15-34		-54	55-	74	7	5+
MALE	FEMALE	MALE	FEMALE	MALE	FEMALE	MALE	FEMALE	MALE	FEMALE	MALE	FEMALE
Lung 71,006	Breast 34,329	Leukemia 550	Leukemia 411	Leukemia 827	Breast 585	Lung 10,124	Breast 8,205	Lung 46,049	Breast 17,403	Lung 14,646	Colon & Rectum 12,626
Colon & Rectum 25,696	Colon & Rectum 27,573	Brain & CNS 344	Brain & CNS 275	Brain & CNS 467	Leukemia 493	Colon & Rectum 2,462	Lung 4,679	Colon & Rectum 13,717	Lung 14,463	Prostate 12,298	Breast 8,129
Prostate 21,674	Lung 24,080	Bone 47	Bone 45	Hodgkin's Disease 335	Brain & CNS 347	Pancreas 1,262	Colon & Rectum 2,210	Prostate 9,047	Colon & Rectum 12,551	Colon & Rectum 9,325	Lung 4,819
Pancreas 11,010	Uterus 10,842	Connective Tissue 43	Kidney 44	Testis 329	Uterus 295	Brain & CNS 1,282	Uterus 2,111	Pancreas 6,490	Ovary 5,992	Pancreas 3,208	Pancreas 3,939
Stomach 8,529	0vary 10,651	Kidney 39	Connective Tissue 43	Melanoma of the skin 261	Hodgkin's Disease 223	Leukemia 1,065	Ovary 2,029	Stomach 4,558	Uterus 5,480	Bladder 3,172	Uterus 2,954

SOURCE: Vital Statistics of the United States, 1978.

RELATIONSHIP OF CANCER TO LEADING CAUSES OF DEATH IN THE UNITED STATES — 1978

RANK	CAUSE OF DEATH	NUMBER OF DEATHS	DEATH RATE PER 100,000 POPULATION	PERCENT OF TOTAL DEATHS
	All Causes	1,927,788	883.4	100.0
1	Diseases of Heart	729,510	334.3	37.8
	Cancer	396,992	181.9	20.6
2 3 4 5 6 7	Stroke	175,629	80.5	9.1
4	Accidents	105,561	48.4	5.5
5	Influenza and Pneumonia	58,319	26.7	3.0
6	Diabetes Mellitus	33,841	15.5	1.8
7	Cirrhosis of Liver	30,066	13.8	1.6
8	Arteriosclerosis	28,940	13.3	1.5
9	Suicide	27,294	12.5	1.4
10	Diseases of Infancy	22,033	10.1	1.1
11	Bronchitis, Emphysema, and Asthma	21,875	10.0	1.1
12	Homicide	20,432	9.4	1.1
13	Congenital Anomalies	12,968	5.9	0.7
14 15	Nephritis and Nephrosis	8,868	4.1	0.5
15	Septicemia and Pyemia	7,800	3.6	0.4
	Other and III-Defined	24,766	113.5	12.8

SOURCE: National Center for Health Statistics, 1978.

ESTIMATED CANCER DEATHS AND NEW CASES BY SEX AND SITE-1981'

	ES	TIMATED DEAT	HS	ESTIN	NATED NEW CA	ASES
SITE	TOTAL	MALE	FEMALE	TOTAL	MALE	FEMALE
All Sites	420,000	227,500	192,500	815,000 1	403,000 1	412,000
Buccal Cavity & Pharynx (Oral) Lip Tongue Salivary Gland Floor of Mouth Other & Unspecified Mouth Pharynx	9,150 175 2,000 700 525 1,550 4,200	6,300 150 1,400 450 400 1,000 2,900	2,850 25 600 250 125 550 1,300	26,600 4,600 4,800 9,600 7,600	18,400 4,100 3,200 5,700 5,400	8,200 500 1,600 3,900 2,200
Digestive Organs Esophagus Stomach Small Intestine Large Intestine Rectum Rectum Liver & Biliary Passages Pancreas Other & Unspecified Digestive	110,500 8,100 13,900 700 46,200 8,700 9,400 22,000 1,500	57,600 5,800 8,400 350 21,500 4,700 4,600 11,500 750	52,900 2,300 5,500 350 24,700 4,000 4,800 10,500 750	194,500 8,800 23,900 2,100 83,000 37,000 13,000 24,200 2,500	99,700 6,200 14,500 1,100 38,000 20,000 6,000 12,700 1,200	94,800 2,600 9,400 1,000 45,000 17,000 7,000 11,500 1,300
Respiratory System Larynx Lung Other & Unspecified Respiratory	110,100 3,700 105,000 1,400	81,000 3,100 77,000 900	29,100 600 28,000 500	135,800 10,700 122,000 3,100	99,000 9,000 88,000 2,000	36,800 1,700 34,000 1,100
Bone, Tissue & Skin Bone Connective Tissue Skin	10,050 1,750 1,600 6,700 4	5,800 1,000 800 4,000	4,250 750 800 2,700	20,900 1,900 4,700 14,300 ²	10,700 1,100 2,600 7,000 ²	10,200 800 2,100 7,300
Breast	37,100	300	36,800	110,900	900	110,000
Genital Organs Cervix, Invasive Corpus, Endometrium Ovary Prostate Other & Unspecified Genital, Male Other & Unspecified Genital, Female	46,400 7,200 3,100 11,400 22,700 1,000 1,000	23,700 - - 22,700 1,000	22,700 7,200 3,100 11,400 - 1,000	151,600 16,000 ³ 38,000 18,000 70,000 5,200 4,400	75,200 - 70,000 5,200	76,400 16,000 38,000 18,000 - - 4,400
Urinary Organs Bladder Kidney & Other Urinary	18,700 10,600 8,100	12,200 7,300 4,900	6,500 3,300 3,200	54,600 37,000 17,600	38,000 27,000 11,000	16,600 10,000 6,600
Eye	400	200	200	1,800	900	900
Brain & Central Nervous System	10,200	5,600	4,600	12,100	6,700	5,400
Endocrine Glands Thyroid Other Endocrine	1,500 1,050 450	600 350 250	900 700 200	10,800 9,900 900	3,300 2,800 500	7,500 7,100 400
Leukemia	15,900	8,900	7,000	23,400	13,000	10,400
Other Blood & Lymph Tissues Hodgkin's Disease Multiple Myeloma Other Lymphomas	21,600 1,700 6,700 13,200	11,200 1,000 3,400 6,800	10,400 700 3,300 6,400	39,500 7,100 9,400 23,000	20,900 4,100 4,800 12,000	18,600 3,000 4,600 11,000
All Other & Unspecified Sites	28,400	14,100	14,300	32,500	16,300	16,20

Note: The estimates of new cancer cases are offered as a rough guide and should not be regarded as definitive. Especially note that year-to-year changes only represent improvements in the basic data.

Incidence estimates are based on rates from NCI SEER Program, 1973-1977.

¹ Carcinoma in situ and non-melanoma skin cancers not included in totals. Carcinoma in situ of the uterine cervix accounts for over 45,000 new cases annually. Non-melanoma skin cancer accounts for about 400,000 new cases annually.

² Melanoma only

³ Invasive cancer only.

⁴ Melanoma 5,000; other skin 1,700.

RESEARCH POSITIONS AT THE NATIONAL CANCER INSTITUTE¹

U

The National Cancer Institute recognizes that one of the most valuable resources to be drawn upon in the fight against cancer is the wealth of scientific talent available in the U. S. and around the world. In an effort to attract and maintain the highest quality scientific staff, two personnel systems are used: the U. S. Civil Service System and the PHS Commissioned Corps. In addition, the Staff Fellowship Program and the NIH Visiting Program have been designed to meet special needs. Special programs are also available for those who qualify.

POSITION	POSITION ELIGIBILITY ANNUAL SALARY		MECHANISM OF ENTRY
. CIVIL SERVICE			
A. Civil Service (tenured)	Appropriate advanced education, experience and knowledge needed by NCI to conduct its programs.	Minimum starting: Ph.D.—\$29,375 Physicians—\$35,688 Maximum: \$50,113	Office of Personnel Management, Contact Director or Laboratory Chief in area of interest or the NCI Personnel Office.
II. SPECIAL APPOINTMENT (OF EXPERTS AND CONSULTANTS		
A. Special Appointment of Experts and Consult- ants (non-tenured ap- pointment which can be extended up to 4 years.	Applicants shall possess outstanding ex- perience and ability as to justify recogni- tion as authorities in their particular fields of activity.	Equivalent to the salary range of GS-13 through GS-18. Maximum: \$50,113	Recommendation by Division Directors Final approval rests with the Director, NCI
III. USPHS COMMISSIONED	CORPS		
Associate Training including	CORD residency deferment program (limited to	tenure, maximum 3 years) ²	
A. Clinical Associate	Graduates of Medical Schools including Internship.	Pay and allowances of Senior Assistant Surgeon or Surgeon of PHS Commissioned Corps.	Apply to Clinical and Professional Educa- tion Section, Clinical Center, National In- stitutes of Health 20205.
B. Research Associate	B. Research Associate Graduates of Medical Schools including Internship.		Apply to Clinical and Professional Education Section, Clinical Center, National Institutes of Health 20205.
C. Staff Associate	Graduates of medical and technical schools, or other doctoral qualifications.	Pay and allowances of Sen- ior Assistant Surgeon of PHS Commissioned Corps.	Apply to Clinical and Professional Educa tion Section, Clinical Center, National In stitutes of Health 20205.
D. Senior COSTEP Program (Medical)	D. Senior COSTEP Pro- Senior Medical Students.		Apply to: Commissioned Personnel Opera- tions Division, Parklawn Building, Room 4-35, 5600 Fishers Lane, Rockville, Mary- land 20852.
IV. VISITING PROGRAM (lim	ited tenure) ³		
A. Visiting Fellow (maximum 3 years)	1-3 years postdoctoral experience or training.	Entrance stipend \$13,000-\$14,200	Contact Director or Laboratory Chief in area of interest.
mum 5 years)		No dependency allowance provided.	
B. Visiting Associates (1 year with renewals to end of project)	3+ years postdoctoral experience or train- ing with appropriate knowledge needed by NCI.	\$17,035-\$32,110	Contact Director or Laboratory Chief is area of interest.
C. Visiting Scientist (duration of project)	6+ years postdoctoral experience with ap- propriate unusual experience and knowl- edge needed.	\$24,703-\$50,113	Contact Director or Laboratory Chief i area of interest.

V. STAFF FELLOWSHIPS

POSITION	ELIGIBILITY	ANNUAL SALARY	MECHANISM OF ENTRY
A. Staff Fellowship	Physician or other doctoral degree equiva- lent awarded within last 5 years, U.S. citizen or non-citizen eligible for naturali- zation within 4 years. Maximum five-year appointment.	Staff Fellows Physicians \$19,740-\$32,236 Other Doctorates \$15,120-\$31,441 Senior Staff Fellows Physicians \$22,365-\$43,796 Other Doctorates \$19,740-\$35,252	Contact Director or Laboratory Chief in area of interest or the NCI Personne Office.
I. CIVIL SERVICE SUMMER	R EMPLOYMENT PROGRAMS		
A. Summer Employment Examination Program	Must be 18 years of age or older (16 if high school graduate).	GS-1 through GS-4 Grade is based on education and/ or experience.	Apply to NIH on or before March 15
B. Summer Undergraduate Program	Students majoring in biological and/or physical sciences or related field, or applicants with appropriate experience.	GS-1 through GS-4 Grade is based on education and/ or experience.	Apply to NIH by March 15. No written test is required.
C. Summer Graduate Program	College graduate, graduate student, planning to attend graduate school, faculty member, or equivalent experience and/or education.	GS-5 through GS-12 For some occupations superior scholastic work may qualify for a higher grade level.	Apply to NIH by March 15.
D. Summer Employment for Needy Youth	Educationally and economically disadvan- taged youths in their formative years (must have reached 16th birthday).	Federal minimum wage.	Register with the local office of the State Employment service and apply to NIH.
E. Stay-in-School Program	Substantially full-time or full-time student at least 16 years of age who needs earnings from employment to continue in school.	Salary is commensurate with duties assigned and student's education and/or experience.	Apply to NIH. No deadline required fo applying. However, no new appointment: are made between May 1 to August 30.
F. The Federal Junior Fel- lowship Program	Graduating high school senior in a public or private school in the Metro. Wash., D. C. area. Must be in upper 10% of graduating class, have applied for admission to an accredited college or university and need financial assistance to attend school.	GS-1 through GS-4	Nominations are submitted directly to th Office of Personnel Management by hig school principals or counselors.
G. Federal Summer Intern Program	Undergraduate student who has completed 2 or more years and is in the upper $\frac{1}{2}$ of class or graduate student in upper $\frac{1}{2}$ of class.	GS-4 through GS-11	Students should contact college place ment office during month of February. NII requests nominations from colleges tha have expressed an interest in the prograr to the Office of Personnel Managemen
II. SPECIAL PROGRAMS			
A. Research Fellow spon- sored by organization other than NIH, PHS.	Determined by sponsoring organization.	Established by sponsoring organization.	Contact Director or Laboratory Chief in area of interest; also apply to sponsorin, agency, e.g., American Cancer Society Eleanor Roosevelt Cancer Foundation Leukemia Society of America, Inc., etc.
B. COSTEP Program (op- erates year-round) Max- imum 120 days per 12- month period.	U. S. Citizen. Must have completed one year of study in a medical, dental or veterinary school; or a minimum of two years of baccalaureate program in a health-related field such as engineering, nursing, pharmacy, etc. May be enrolled in a master's or doctoral program in a health-related field (designated by the Assistant Secretary for Health). Physical requirements of PHS Commissioned Corps. Plans to return to college.	Pay and allowance of a Commissioned Officer, Jun- ior Asst. Grade.	Apply to PHS Commissioned Corps, COS TEP SECTION, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20852

International reputation, productivity, demonstrated ability in biomedical field.


Does not necessarily indicate that positions are currently available at the National Cancer Institute.
 Appointments are made upon intellectual attainment and demonstrated research interest and ability matched to NCI's needs.
 Under most circumstances, the various visiting programs are limited to non-citizens.

\$40,000 per annum


Recommendation to Fogarty Center by Institute Director or Scientist. Contact Director in area of interest.

to return to college.

C. Fogarty International Scholars



NCI BUDGET ADMINISTRATION PROCESS—UNDER CANCER ACT OF 1971



NOTE: SIMULTANEOUS ACTIVITIES BY MORE THAN ONE ORGANIZATION INDICATE COOPERATIVE EFFORTS


LEGEND:



REVIEW




NCI EXTRAMURAL FUNDS - FISCAL YEAR 1980



	1971 A	CTUAL	1972 AC	CTUAL	1973 A	CTUAL	1974 AC	TUAL
	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCEN OF TOTA
Group I – Investigator Initiated								
Regular Research Grants	\$ 44,133	24.2	\$ 59,207	18.9	\$ 73,412	21.1	\$ 99,415	21.5
Clinical Cooperative Groups	7,013	3.9	10,102	3.2	12,791	3.7	16,196	3.5
Program Projects - PO1's	30,205	16.6	38,415	12.2	52,008	14.9	71,997	15.6
Clinical Education Program	-		-		-		2-	-
Research Career Program	2,012	1.1	2,026	.7	1,818	.5	1,673	.4
Fellowships and Training	12,560	6.9	18,395	5.9	13,888	4.0	23,562	5.1
Organ Site			638	.2	3,950	1.1	10,007	2.2
Cancer Centers - Core Support	6,174	3.4	10,090	3.2	13,002	3.7	17,575	3.8
Subtotal	102,097	56.1	138,873	44.3	170,869	49.0	240,525	52.1
Group II – Co-Initiated								
Cancer Res. Emphasis Grants								
(CREG)					_		_	200
Research Grants	27,547	15.1	46,802	14.9	61,187	17.6	94,964	20.5
Subtotal	27,547	15.1	46,802	14.9	61,187	17.6	94,964	20.5
Group III – NCI/NCP Initiated	3							
Research Support Contracts	44,945	24.7	63,194	20.2	64,838	18.6	72,365	15.7
Interagency Agreements	5,704	3.1	12,053	3.8	10,136	2.9	13,031	2.8
Subtotal	50,649	27.8	75,247	24.0	74,974	21.5	85,396	18.5
Group IV – Other Resources								
Planning Grants	1,889	1.0	1,698	.5	2,500	.7	2,880	.6
Construction Grants	-	1992	47,004	15.0	34,737	10.0	31,692	6.9
Construction Contracts			3,999	1.3	4,067	1.2	6,398	1.4
Subtotal	1,889	1.0	52,701	16.8	41,304	11.9	40,970	8.9
			ranginan mangr		U a OU STAN TOO			
Total Percent of Total NCI Budget	182,182	100.0 80.3	313,623	100.0 84.2	348,334	100.0 81.9	461,755	79.5
In-House Research	20,594	9.1	25,696	6.9	33,032	7.8	40,364	6.9
Management & Support	24,176	10.6	33,246	8.9	39,072	9.2	46,169	7.9
(NIH Management Fund)	(10,917)	(4.8)	(12,910)	(3.5)	(15,194)	(3.6)	(16,754)	(2.9
Cancer Control (Grants	120		37 77 37		B 01 (10)		0-1 170 1 87	
& Contracts)	-		-		4,969	1.1	32,826	5.7
Subtotal	44,770	19.7	58,942	15.8	77,073	18.1	119,359	20.5
Total NCI	\$226,952	100.0	\$372,565	100.0	\$425,407	100.0	\$581,114	100.0

1975 ACTUAL		1976 ACTUAL		1977 AC	TUAL	1978 AC	TUAL	1979 AC	TUAL	1980 AC	TUAL
DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL	DOLLARS	PERCENT OF TOTAL
\$115,195	21.4	\$130,633	22.7	\$140,159	23.0	\$158,716	24.7	\$188,488	27.3	\$213,610	29.0
19,213	3.6	23,263	4.0	27,121	4.5	29,774	4.6	32,021	4.6	36,884	5.0
84,536	15.7	80,029	13.9	83,453	13.7	88,058	13.7	93,953	13.6	104,094	14.1
5,033	.9	7,698	1.3	8,996	1.5	9,952	1.5	11,404	1.7	10,906	1.5
2,806	.5	3,243	.6	3,507	.6	4,399	.7	4,771	0.7	5,357	0.7
23,104	4.3	18,160	3.1	19,791	3.3	20,129	3.1	20,139	2.9	27,260	3.7
11,167	2.1	14,090	2.5	14,711	2.4	16,194	2.5	17,032	2.5	17,554	2.4
30,096	5.6	47,803	8.3	55,132	9.1	60,348	9.4	64,364	9.3	67,421	9.1
291,150	54.1	324,919	56.4	352,870	58.1	387,570	60.2	432,172	62.6	483,086	65.5
-		2,577	.5	7,266	1.2	9,412	1.5	7,894	1.1	7,771	1.1
105,076	19.5	111,524	19.3	110,740	18.6	120,359	18.6	81,119	11.8	57,446	7.8
105,076	19.5	114,101	19.8	118,006	19.4	129,771	20.1	89,013	12.9	65,217	8.8
82,916	15.4	96,509	16.7	94,229	15.5	87,806	13.6	130,161	18.9	151,305	20.5
11,593	2.2	13,262	2.3	19,414	3.2	21,621	3.4	20,734	3.0	22,595	3.1
94,509	17.6	109,771	19.0	113,643	18.7	109,427	17.0	150,895	21.9	173,900	23.6
2,568	.4	2,803	.5	1,199	.2	632	.1	271	0.1	221	
30,000	5.6	20,000	3.5	16,000	2.6	12,000	1.9	12,452	1.8	10,814	1.5
14,976	2.8	4,721	.8	5,992	1.0	4,544	.7	4,878	0.7	4,618	0.6
47,544	8.8	27,524	4.8	39,191	3.8	17,176	2.7	17,601	2.6	15,653	2.1
			-								:
538,279	100.0 77.0	576,315	100.0 75.7	607,710	100.0 74.6	643,944	100.0 73.8	689,681	100.0 73.6	737,856	100.0 73.9
50,532	7.2	61,243	8.0	67,855	8.3	79,217	9.1	88,944	9.5	98,665	9.9
61,935	8.9	69,876	9.2	80,184	9.8	86,594	9.9	91,167	9.7	97,863	9.8
(20,248)	(2.9)	(23,037)	(3.0)	(26,817)	(3.3)	(30,150)	(3.5)	(35,622)	(3.8)	(39,549)	(4.0)
48,574	6.9	54,016	7.1	59,208	7.3	62,614	7.2	66,904	7.2	63,663	6.4
161,041	23.0	185,135	24.3	207,247	25.4	228,425	26.2	247,015	26.4	260,191	26.1
\$699,320	100.0	\$761,450	100.0	\$814,957	100.0	\$872,369	100.0	\$936,696	100.0	\$998,047	100.0

NCI RESEARCH PROGRAMS-FISCAL YEAR 1980




TOTAL NCI DOLLARS BY MECHANISMS—FISCAL YEAR 1980


(DOLLARS IN THOUSANDS)


	AMOUNT	MECHANISM	PERCENT OF TOTAL	
	RESEARCH F	PROJECT GRANTS		
\$321,326	\$206,874 3,387 6,971 104,094		20.7 0.4 0.7 10.4	32.2%
	RESEARCH (CENTERS GRANTS		
\$67,642	221 67,421	Exploratory Grants Center Core Grants	0.01 6.8	6.8%
	OTHER RESE	ARCH GRANTS		
\$74,556	2,410 939 4,720 10,906 36,884 17,554 343 800	Scientific Evaluation Conference Grants Research Career Programs Clinical Education Programs Cooperative Clinical Research National Organ Site Program Veterinary Pathology Awards Cooperative Agreements	0.2 0.09 0.5 1.1 3.7 1.8 .03 .08	7.5%
	TRAINING P	ROGRAM		
\$27,260	4,087 23,173	National Research Service Awards—Individual National Research Service Awards—Institutional	0.4 2.3	2.7%
	RESEARCH A	AND RESOURCE CONTRACTS		
\$231,346	231,346	Research and Resource Contracts	23.2	23.2%
****	CANCER CON	ITROL		
\$66,993	66,993	Cancer Control	6.7	6.7%
	CONSTRUCT	ION		4.50/
\$15,432	15,432	Construction	1.5	1.5%
	IN-HOUSE			
\$193,492	144,009 38,868 10,615	Intramural Research Direct Operations Program Management	14.4 3.9 1.1	19.4%
	\$998,047	TOTAL NCI	100.0	

NCI PROGRAM STRUCTURE-FISCAL YEAR 1980




CANCER CONTROL OBLIGATIONS BY MECHANISM-FISCAL YEARS 1973-1980





The Management Fund provides for the financing of certain common research supporting services and administrative activities which are required in the operating of NIH.


NCI GRANTS ADMINISTRATION PROCESS - UNDER CANCER ACT OF 1971



"NCAB MEETS NOT LESS THAN FOUR TIMES PER YEAR

DECISION

NCI CONTRACTS ADMINISTRATION PROCESS—UNDER CANCER ACT OF 1971



NOTE: SIMULTANEOUS ACTIVITIES BY MORE THAN ONE ORGANIZATION INDICATE COOPERATIVE EFFORTS.


OPERATION
REVIEW
DECISION

NORMAL FLOW


--- NON-COMPETITIVE CONTRACTS

* AD HOC COMMITTEES MAY BE USED— INCLUDES OUTSIDE SCIENTISTS.





DISTRIBUTION OF CANCER CONTROL GRANTS AND CONTRACTS—FISCAL YEAR 1980



INSTITUTIONS RECEIVING MORE THAN \$1,000,000 FROM THE NATIONAL CANCER INSTITUTE IN FISCAL YEAR 1980

NAME OF INSTITUTION	GRANTS	CONTRACTS	CONSTRUCTION	TOTAL	LOCATION	
	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	đ 004		t 7.00F	Alabama	
Alabama, University of	\$ 7,581 7,457	\$ 224 74	3 -	\$ 7,805 7,531	New York	
Albert Einstein College of Medicine	969	949	22111 <u>-</u> 1111-1	1.918	Pennsylvania	
American College of Obstetrics and Gynecology	1.148	_ 5.,5		1,148	Illinois	
American College of Radiology	2,031	1,171		3,202	Illinois	
American Health Foundation	3,050	891		3,941	New York	
Arizona, University of	4,348	140		4,488	Arizona	
Arthur D. Little, Inc.	- 400	3,153		3,153	Massachusetts Ohio	
Battelle Memorial Institute	1,400	6,148 382		7,548	Texas	
Baylor College of Medicine	5,010	1,428		5,392 1,428	Ohio	
Ben Venue Laboratories, Inc. Boston University Medical Center	1.968	41		2,009	Massachusetts	
Bowman Gray School of Medicine of Wake Forest University	1,591	36		1.627	North Carolina	
California State Department of Health		2,059		2,059	California	
California, University of	33,098	3,961	965	38,024	California	
Case Western Reserve University	2,368	199		2,567	Ohio	
Charles River Breeding Labs	7,000	2,330	11111 H	2,330	Massachusetts	
Chicago, University of	7,960	829		8,789 1,009	Illinois Massachusetts	
Children's Hospital Medical Center	1,009 1,552	435		1,987	Pennsylvania	
Children's Hospital of Philadelphia	1,393	455		1,393	California	
City of Hope National Medical Center	3,915	2		3,917	New York	
College of Medicine and Dentistry of New Jersey	1,433	238		1,671	New Jersey	
Colorado State University	1,700	-		1,700	Colorado	
Colorado, University of, Medical Center	2,934	-		2,934	Colorado	
Columbia University	8,658	1,005	THE RESERVE	9,663	New York	
Community Blood and Plasma Service	-	1,190		1,190	Alabama	
Connecticut, University of, Health Center	1,658		170	1,658	Connecticut	
Cornell University Medical Center	3,541 2,448	112	170	3,711 2,560	New York New Hampshire	
Dartmouth College Duke University	7,032	995		8,027	North Carolina	
Electro-Nucleonics Laboratories, Inc	7,052	1,320	A PARTY OF THE PAR	1,320	Maryland	
Emory University	1.449	889		2,338	Georgia	
Energy, Department of	1.251	4,829	2	6,080	New York	
Enviro Control, Inc		2,421		2,421	Maryland	
Environmental Protection Agency		2,081		2,081	Dist. of Col.	
Florida, University of	2,252	195		2,447	Florida	
Flow Laboratories, Inc.		2,748		2,748	Maryland	
Fox Chase Cancer Center	1,603	750		2,353 2,085	Pennsylvania Pennsylvania	
Franklin Institute Research Labs	10.456	2,085 1,701	4,604	16,761	Washington	
Frontier Science and Technology Research Foundation, Inc.	10,456	3,296	4,004	3,296	New York	
George Washington University	1,284	277		1,561	Dist. of Col.	
Georgetown University	2,010	1,349		3,359	Dist. of Col.	
Georgia, University of	1,091	115		1,206	Georgia	
Hahnemann Medical College and Hospital	1,305	-		1,305	Pennsylvania	
Harlan Industries, Inc		1,985		1,985	Indiana Massachusetts	
Harvard University	9,207	588	111	9,906	Massachusetts Hawaii	
Hawaii, University of	1,151	968		2,119 2,364	Virginia	
Hazleton Laboratories, Inc	1,489	2,364		1,490	Dist. of Col.	
IIT Research Institute	67	1.959		2,026	Illinois	
Illinois Cancer Council	1.685	209		1,894	Illinois	
Illinois, University of	2,077	663	4	2,740	Illinois	
Indiana University Foundation	1,731	543		2,274	Indiana	
Institute for Cancer Research	7,267	-		7,267	Pennsylvania	
International Agency for Research on Cancer	9 3177	1,110		1,110	France	
lowa, University of	2,108	2,064		4,172	lowa	
IRDC	- 400	2,961	TATAL PROPERTY AND ADDRESS OF THE PARTY AND AD	2,961 1,899	Michigan Maine	
Jackson Laboratory	1,498	401		1,967	Pennsylvania	
Johns Hopkins University	1,967 13,509	1,772	2,895	18,176	Maryland	
Kaiser Foundation Hospitals	13,509	999		1,191	California	
Kansas, University of	_	2,995	_	2,995	Kansas	
Kansas, University of, College of Health Sciences & Hosp	2,336		TOTAL PROPERTY.	2,336	Kansas	
Kentucky, University of	1,714	298	<u> </u>	2,012	Kentucky	
La Jolla Cancer Research Foundation	1,118	272100C	HH - 1915	1,118	California	
Life Sciences, Inc.	193	1,244		1,437	Florida	
Litton Bionetics, Inc.	Tara	32,251		32,251 1,589	Maryland Louisiana	
Louisiana State University Medical Center	1,018	571		5,701	Maryland	
Maryland, University of	1,092	4,609 3,826		3,826	Massachusetts	
Mason research mistrute/Edox	-	3,020		0,040	mussachusetta	

NAME OF INSTITUTION	GRANTS	CONTRACTS	CONSTRUCTION	TOTAL	LOCATION
Massachusetts General Hospital	\$ 4,592	\$ 517	\$	\$ 5,109	Massachusetts
Massachusetts Institute of Technology	6,609	-		6,609	Massachusetts
Mayo Foundation	4,628	2,414		7,042	Minnesota
Medical College of Virginia	2,617	1	-	2,618	Virginia
Medical College of Wisconsin	1,022	95	——————————————————————————————————————	1,117	Wisconsin
Meloy Laboratories, Inc.	7.000	5,156	2000 T 022	5,156	Virginia
Memorial Hospital for Cancer and Allied Diseases	4,496	2,540 481		7,036 3,501	New York Florida
Miami, University of	3,020 3,349	5,879	300	9,528	Michigan
Michigan State University	1.492	75	-	1.567	Michigan
Michigan, University of, Ann Arbor	3,101	-	100 200	3,101	Michigan
Microbiological Associates	2	3,240	± 1	- 3,240	Maryland
Midwest Research Institute	110	2,417	. 72	2,527	Missouri
Minnesota, University of	6,167	1,652	222	8,041	Minnesota
Mount Sinai School of Medicine	5,717	813 1,201	_	6,530	New York
National Naval Medical Center	1,661	1,143		1,201 2,804	Maryland Nebraska
New Mexico, University of	3,910	209	Ξ	4,119	New Mexico
New York Department of Health	11,668	944	645	13,257	New York
New York Medical College	1,400	186		1,586	New York
New York University Medical Center	6,470	223		6,693	New York
North Carolina, University of	3,736	259		3,995	North Carolina
Northern California Cancer Program	2,268	364	-	2,632	California
Northwestern University	2,093 4,542	19 843	-	2,112 5,385	Illinois Ohio
Ohio State University Research Foundation	1.816	47		1,863	Oregon
Pennsylvania State University Hershey Medical Center	2.989	_ 4/		2,989	Pennsylvania
Pennsylvania, University of	6,180	325		6,505	Pennsylvania
Pittsburgh, University of	2,259	2,274		4,533	Pennsylvania
Porter, Novelli and Associates		1,020		1,020	Dist. of Col.
Purdue University, West Lafayette	1,268	- 61		1,268	Indiana
Research Foundation of the State University of New York	5,262 6,664	81 432	-	5,343 7,096	New York New York
Rochester, University of	3,947	10		3,957	New York
Roger Williams General Hospital	1,346			1,346	Rhode Island
Rush Presbyterian-St. Luke's Medical Center	1,862	709		2,571	Illinois
Saint Louis University School of Medicine	1,443	282	-	1,725	Missouri
Salk Institute for Biological Studies	3,667	121		3,788	California
Scripps Clinic and Research Foundation	4,671	257 632		4,928	California
Sidney Farber Cancer Institute	13,562	1,678	_	14,194 1,678	Massachusetts California
Simonsen Laboratories	20,803	1,905		22,708	New York
Southern California, University of	9,293	2,101		11,394	California
Southern Research Institute	2.144	3,972		6.116	Alabama
SRI International	1,128	3,330	-	4,458	California
St. Jude Children's Research Hospital	5,264	-	902	6,166	Tennessee
Stanford University	8,321	562	100 m = 100 m	8,883	California
Temple University	4,075 2,609	312 113		4,387 2,722	Pennsylvania Tennessee
Tennessee, University of	23,130	4.548		27,678	Texas
Tracor Jitco, Inc.	20,100	21,777	_	21,777	Maryland
Tufts University School of Medicine	2,291	11		2,302	Massachusetts
Tufts-New England Medical Center	1,172		-	1,172	Massachusetts
University City Science Center		1,187	-	1,187	Pennsylvania
Utah, University of	3,046	550	-	3,596	Utah
Vanderbilt University Medical Center	1,793 1,871	273 92	-	2,066 1,963	Tennessee Vermont
Vermont, University of, College of Medicine	1,0/1	2,686	_	2,686	Dist. of Col.
Virginia, University of, Charlottesville	1,082	-		1,082	Virginia
VSE Corporation	-,00-	1,087		1,087	Virginia
Warner Lampert	-	1,965	_	1,965	Michigan
Washington University	5,365	123		5,488	Missouri
Washington, University of	3,430	2,211	-	5,641	Washington
Wayne State University	1,425	268	-	1,693	Michigan
Westat, Inc	12,973	2,760	-	2,760 14,243	Maryland Wisconsin
Wisconsin, University of	5,873	1,270		5,873	Pennsylvania
Worcester Foundation for Experimental Biology	1,686		_	1,686	Massachusetts
Yale University School of Medicine	11,877	1,614	_	13,491	Connecticut

TOTALS PERCENT OF TOTAL AWARDED ABOVE		Control of the contro	
TOTAL NCI FISCAL YEAR 1980 OBLIGATIONS		1.0	100.0
PERCENT OF NCI TOTAL OBLIGATIONS	21.0	1.1	68.5


DISTRIBUTION OF NCI CONTRACTS-FISCAL YEAR 1980

		PROGRAM DISTRIBUTION		
PERCENT OF OTAL NUMBER OF CONTRACTS	NUMBER OF CONTRACTS	NCI PROGRAM AREA	THOUSANDS OF DOLLARS	PERCENT OF TOTAL DOLLARS
13.6	117	Division of Cancer Biology and Diagnosis	\$ 20,968	7.8
32.2	277	Division of Cancer Treatment	79,005	29.4
42.7	368	Division of Cancer Cause and Prevention	128,775	47.8
	89	Division of Resources, Centers, and Community Activities	37,737	14.0
10.3	10	Office of the Director	2,598	1.0
cludes Interagency Agreements	861	TOTALS	\$269,083	

		INSTITUTIONAL DISTRIBUTION		
PERCENT OF TOTAL NUMBER OF CONTRACTS	NUMBER OF CONTRACTS	TYPE OF INSTITUTION	THOUSANDS OF DOLLARS	PERCENT OF TOTAL DOLLARS
23.5	202	Profit-Making	\$114,858	42.7
24.0	293	Academic	53,631	
34.0	212	Non-Profit	59,345	19.9
24.6	69	Federal Government	27,944	22.1
8.0	25	State and Local Government	6,043	10.4
7.0	60	Foreign	7,262	2.2
	861	TOTALS	\$269,083	


NOTE: Does not include contracts that are not in direct support of research or control, such as Cancer Communications, Program Planning, and Construction contracts.

DISTRIBUTION OF NCI RESEARCH GRANTS BY VALUE OF GRANT AWARD—FISCAL YEAR 1980



Excludes Training and Fellowship Awards, Cancer Control Grants, Construction Grants, Clinical Education, and Career Awards. Includes Clinical Trials and CREG Awards.

DISTRIBUTION OF THE GRANT DOLLAR-FISCAL YEAR 1980 (DOLLARS IN THOUSANDS) **TOTAL GRANT OBLIGATIONS** \$527,818 PERSONNEL 45.5¢ \$239,951 INDIRECT COSTS 26.8% \$141,566 CONSTRUCTION CONTRACTUAL 2.0¢ \$10,814 OR THIRD PARTY COSTS 1.9¢ \$10,196



FOREIGN RESEARCH GRANTS AND CONTRACTS — FISCAL YEAR 1980

	NUMBER OF GRANTS	GRANT DOLLARS AWARDED	NUMBER OF CONTRACTS	CONTRACT DOLLARS AWARDED	TOTAL DOLLARS AWARDED	PERCENT OF TOTAL AMOUNT AWARDED
Australia	4	\$ 181,733	2	\$ 114,817	\$ 296,550	2.6
Austria		_	3	57,983	57,983	0.5
Belgium	1	237,090	3	421,265	658,355	5.8
Canada	14	584,037	9	911,445	1,495,482	13.1
Colombia	_	_	1	50,692	50,692	0.4
Denmark	1	39,135	-	_	39,135	0.3
East Africa	_	_	1	125,000	125,000	1.1
England	3	320,828	11	885,491	1,206,319	10.6
Finland	3	106,800	_	_	106,800	0.9
France	1	34,395	9	1,393,998	1,428,393	12.5
Germany	_	_	2	33,200	33,200	0.3
Ghana	_	-	1	75,343	75,343	0.7
Israel	9	621,429	15	392,693	1,014,122	8.9
Italy	3	116,690	8	673,604	790,294	6.9
Japan	-	_	6	715,835	715,835	6.3
Netherlands	1	15,000	3	90,000	105,000	0.9
Norway	-	-	1	81,963	81,963	0.7
Portugal	i	_	1	5,000	5,000	0.0
Scotland	a_a 1	_	5	304,386	304,386	2.7
South Africa	1	59,254	_	- 2	59,254	0.5
Sweden	7	523,086	6	391,880	914,966	8.0
Switzerland	3	1,008,728	2	857,456	1,866,184	16.3
TOTAL	51	\$3,848,205	89	\$7,582,051	\$11,430,256	100.0

APPROPRIATIONS OF THE NCI 1938-1981

1938 1939		0.21%
1940 THROUG	GH 1946 \$3,879,570	\$21,000,470
1947 1948	1,820,900 14,500,000 22,000,000	
1949	22,000,000	2.77%
1950 7	THROUGH 1956 \$149,481,750	\$276,315,750
1958 .		,000
	1960 THROUGH 1966 \$958,954,00	\$1,393,234,000
19	67 175 968 18 1969 1 1970 1 1971 1	6,656,000 83,356,000 85,149,500 190,486,063 6.09% \$606,018,563
76.96% \$7,654,331,500	1976 "TQ" 1977 1978 1979 1980	492,205,000

NOTEWORTHY DATES FOR NCI APPROPRIATIONS

Exceeded \$1,000,000 in 1947. Exceeded \$50,000,000 in 1958. Exceeded \$100,000,000 in 1961. Exceeded \$1,000,000,000 in 1980.

TRANSITION QUARTER ("TQ")—July 1, 1976 through September 30, 1976—The Interim Period in the changing of the Federal Fiscal Year from July 1 through June 30, to October 1 through September 30.

TOTAL (1938 through 1981).....

*Includes \$18,163,000 for training funds provided by Continuing Resolution.

² Includes \$3,201,000 for training funds provided by Continuing Resolution.

³ Included \$20,129,000 for training funds provided by Continuing Resolution.

* 1980 appropriation authorized under a Continuing Resolution.
5 1981 appropriation authorized under a Continuing Resolution.


\$9,950,900,283

COMPARISON OF DOLLARS, POSITIONS AND SPACE

			DOLLARS			POSITIONS			SPACE	
		OBLIGATIONS (\$000's)	PERCENT OF INCREASE OVER BASE YEAR	PERCENT OF INCREASE OVER PRIOR YEAR	ACTUAL FULL-TIME PERMANENT EMPLOYEES	PERCENT OF INCREASE OVER BASE YEAR	PERCENT OF INCREASE OVER PRIOR YEAR	ALLOCATED SPACE (SQUARE FEET)*	PERCENT OF INCREASE OVER BASE YEAR	PERCENT OF INCREASE OVER PRIOR YEAR
	1971	232,855	Base Year	-	1426	Base Year	-	321,230	Base Year	=
	1972	378,636	62.6	62.6	1665	16.8	16.8	329,587	2.6	2.6
	1973	431,245	85.2	13.9	1736	21.7	4.3	357,972	11.4	8.6
	1974	581,149	149.6	34.8	1805	26.6	4.0	381,436	18.7	6.6
FISCAL YEAR	1975	699,320	200.3	20.3	1849	29.7	2.4	382,485	19.1	0.2
FISCAL	1976	760,751	226.7	8.8	1955	37.1	5.7	387,324	20.6	1.3
	1977	814,957	250.0	7.1	1986	39.3	1.6	428,285	33.3	10.6
	1978	872,369	275.0	7.2	1969	38.1	-0.9	491,725	53.1	14.8
	1979	936,696	302.3	7.4	1973	38.4	0.2	493,156	53.5	0.3
	1980	998,047	328.6	6.5	1837	28.8	-6.7	467,730	45.6	-5.2


^{*}Does not include field station-assigned space.

NATIONAL CANCER INSTITUTE OBLIGATIONS AND OUTLAYS



OBLIGATIONS: Orders placed, grants and contracts awarded, salaries earned and similar financial transactions which legally utilize or reserve an appropriation for expenditure. **OUTLAYS:** Payments (cash or checks) made from current or prior year appropriations.

NCI GRANT AWARDS - 1971-1980



NCI REGULAR GRANT AWARDS — 1974-1980 (Including Clinical Cooperative Groups)

FISCAL	TYPE AWARD	REG	UESTED	APPROVED		AWARDED		PERCENT
YEAR	TYPE AWARD	NUMBER	AMOUNT	NUMBER	AMOUNT	NUMBER	AMOUNT	FUNDED
1974	Competing	W 100 1 100 N		Venera		va seen		
	New	1,382 379	\$100,717 33,651	909 336	\$ 45,713 22,815	500 285	\$ 27,824 20,413	55.0 84.8
	Total	1,761	134,368	1,245	68,528	785	48,237	63.1
	Non-Competing	-		-		1,049	62,803	-
1975	Competing New Renewals	1,509 555	\$108,621 55,314	979 429	\$ 48,023 31,876	581 349	\$ 30,605 27,949	59.3 81.4
	Total	2,064	163,935	1,408	79,899	930	58,554	66.1
	Non-Competing	-		-		1,112	72.917	-
1976	Competing New	1,499 517	\$113,135 53,992	910 376	\$ 47,342 28,070	388 257	\$ 22,230 21,236	42.6 68.4
	Total	2,016	167,127	1,286	75,412	645	43,466	50.2
	Non-Competing	-		-		1,486	108,818	-
1977	Competing New	1,756 728	147,591 87,162	1,071 578	\$ 60,155 50,221	398 303	\$ 23,781 32,436	37.2 52.4
4	Total	2,484	234,753	1,649	110,376	701	56,217	42.5
	Non-Competing	-		-		1,412	104,431	-
1978	Competing New	1,854 752	\$153,528 97,937	1,264 617	\$ 75,014 57,131	513 381	\$ 32,591 38,905	40.6 61.8
	Total	2,606	251,465	1,881	132,145	894	71,496	47.5
	Non-Competing	-		-		1,341	111,916	-
1979	Competing New	1,950 653	\$177,989 80,521	1,414 570	\$ 97,596 52,012	576 334	\$ 45,287 35,025	40.7 58.6
	Total	2,603	258,510	1,984	149,608	910	80,312	45.9
	Non-Competing	-		-		1,485	141,198	-
1980	Competing New Renewals	1,891 632	\$188,988 89,866	1,401 610	\$103,389 62,289	470 346	\$ 37,605 39,167	33.5 56.7
	Total	2,523	278,854	2,011	165,678	816	76,772	40.6
1	Non-Competing			-		1,739	171,312	-